Dzintars Gotham
Biographic Data
| ID | 9066443 |
|---|---|
| NAME | Dzintars Gotham |
| GIVEN NAMES | Dzintars |
| FAMILY NAME | Gotham |
| SIGNATURE | GOTHAM D |
| AFFILIATIONS | Oldham Council |
| ORCID | 0000-0003-0359-1259 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Reimbursement models to tackle market failures for antimicrobials
INTRODUCTION: The pipeline of new antibacterials remains limited. Reasons include low research investments, limited commercial prospects, and scientific challenges. To complement existing initiatives such as research grants, governments are exploring policy options for providing new market incentives to drug developers. MATERIALS AND METHODS: Reimbursement interventions for antibacterials in France, Germany, Sweden, US, and UK were reviewed and a…
No prominent works on this page.
Reimbursement models to tackle market failures for antimicrobials
INTRODUCTION: The pipeline of new antibacterials remains limited. Reasons include low research investments, limited commercial prospects, and scientific challenges. To complement existing initiatives such as research grants, governments are exploring policy options for providing new market incentives to drug developers. MATERIALS AND METHODS: Reimbursement interventions for antibacterials in France, Germany, Sweden, US, and UK were reviewed and a…
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Business (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Medicine (2 works) · Pharmaceutical Economics and Policy (2 works) · Accounting (1 work) · Antibiotic Use and Resistance (1 work) · Bedaquiline (1 work) · Biosimilars and Bioanalytical Methods (1 work) · Clinical trial (1 work) · Cost effectiveness (1 work)